|
Venture Capital Outlook: Reason for Hope or Cause for Conservatism
Thursday, December 11, 2008 | 3pm-6:30pm
“Black October hit the biotech industry hard” according to Steve Burrill’s most recent market assessment, but Silicon Valley Business Journal reports the “biotech sector edging out software as the number one industry last quarter-with the life sciences sector (biotechnology and medical devices combined) seeing a 10% increase in VC investing with $2.2 billion going into 207 deals.”
Join investors who are leading these deals to debate and discuss current market trends and what we can expect for 2009. Conflicting reports of impending doom or optimistic forecasts for the future of life sciences; we will get the answers.
Panelists include:
- Ellen Koskinas, Partner, InterWest Partners LLC: a successful Venture Capitalist with outstanding board member experience, and who led - prior to InterWest - Guidant's acquisition of CardioThoracic Systems.
- Mohan Iyer, Managing Director, Merchant Banking, Burrill & Company: His expertise is in representing innovative companies in transformative transactions, particularly strategic partnering and/or M&A. During his three+ years at Burrill & Company, he has advised emerging and public biotech companies on strategic transactions in multiple therapeutic areas, as well as in diagnostic and drug discovery/CRO services.
- Ted Driscoll, Venture Partner, Claremont Creek Ventures: a well-known venture capitalist, but also an angel with Sand Hills Angels, a scientist with 40+ granted patents, and a true entrepreneur who helped found five successful companies in imaging-related markets.
- Yael Weiss, Director, Worldwide Licensing & External Research,
Merck Research Laboratories: Yael joined MSD Israel as medical director in the beginning of 2004 and in 2007 she joined Merck's Licensing group in San Francisco as a scientific scout responsible for identification of licensing opportunities emanating from the West Coast.
- Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP: whose practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings, and technology transactions.
Click here for speakers' bios and to read more about this event»
This event is typically sold out, therefore please register early to secure your spot!
-Panel + Networking Reception:
 -Regular Price: $60 before or on Dec. 5 | $70 on-site*
-Partners' Network: $40 before or on Dec. 5 | $50 on-site*
-BioCenter Members: Free (Please RSVP to Lauren Wakefield directly)
-Networking Reception only: $30 before or on Dec. 5 | NO on-site registrations!
*For on-site registration (if space allows): please bring CASH or CHECK!
Venue
ABD
Insurance-a Wells Fargo Company
305 Walnut Street
Redwood City, CA 95063
Click here for directions!
For Lease
Suite 231— Office or Manufacturing Space
Square footage: 800 square feet
Location of suite: Internal suite
Available Date: December 1, 2008
4 foot fumehood
Bench (2)
Centralized gas
Sink
RO/DI water system
Centralized vacuum
Emergency generator
Emergency shower
Emergency eyewash
Separate and online HVAC
Flammable and corrosive cabinet
Gas cylinder racks and hook ups
Storage
Cabinets/shelving
110V/220V
Voice
Data
Private office with office furniture provided
Reception/storage area
Apply»
Upcoming BioCenter Program
BioCenter California Clean Tech Open House | Dec. 10, 2008
The San Jose BioCenter will be hosting a California Clean Tech Open House for both the semi-finalists and the finalists on Wednesday, December 10, 2008 from 2:30 - 3:30 PM followed by our l holiday networking reception. Attendees will inlcude BioCenter clients, mentors, and leaders from the industry.
Venture Capital Outlook: Reason for Hope or Cause for Conservatism | Dec. 11, 2008“Black October hit the biotech industry hard” according to Steve Burrill’s most recent market assessment, but Silicon Valley Business Journal reports the “biotech sector edging out software as the number one industry last quarter-with the life sciences sector (biotechnology and medical devices combined) seeing a 10% increase in VC investing with $2.2 billion going into 207 deals.” Join investors who are leading these deals to debate and discuss current market trends and what we can expect for 2009. Conflicting reports of impending doom or optimistic forecasts for the future of life sciences; we will get the answers. Read More
BioCenter Expansion: Reserve Your Lab Now!
The BioCenter recently kicked off the expansion to 80,000sf with second stage lab spaces of 5,000 – 10,000 sf. Applications to reserve lab spaces are now available. If you’d like to be considered as a BioCenter company, please click and fill in the application form. The BioCenter does not take any IP or equity stakes. Our goal is to level the playing field for small companies by providing the same type of infrastructure that project teams in large companies have access to. For more information, please contact Gayle Fagan at gayle@sjbiocenter.com or 408.960.3805.
Review the BioCenter Services Offering»
Review our Criteria»
|
|
